Evidence map›Paper›PMID 31595378›Full record

ArticleJournal of neurology2020

Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders.

Kasper Katisko, Antti Cajanus, Olli Jääskeläinen, Aleksi Kontkanen, Päivi Hartikainen, Ville E Korhonen, Seppo Helisalmi, Annakaisa Haapasalo, Heli Koivumaa-Honkanen, Sanna-Kaisa Herukka and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 4 pooled it
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 4 syntheses or guidelines pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Kasper KatiskoInstitute of Clinical Medicine-Neurology, University of Eastern Finland, Yliopistonranta 1C, 1627, 70211, Kuopio, Finland.
Antti CajanusInstitute of Clinical Medicine-Neurology, University of Eastern Finland, Yliopistonranta 1C, 1627, 70211, Kuopio, Finland.
Olli JääskeläinenInstitute of Clinical Medicine-Neurology, University of Eastern Finland, Yliopistonranta 1C, 1627, 70211, Kuopio, Finland.
Aleksi KontkanenInstitute of Clinical Medicine-Neurology, University of Eastern Finland, Yliopistonranta 1C, 1627, 70211, Kuopio, Finland.
Päivi HartikainenInstitute of Clinical Medicine-Neurology, University of Eastern Finland, Yliopistonranta 1C, 1627, 70211, Kuopio, Finland.
Ville E KorhonenNeuro Center, Neurosurgery, Kuopio University Hospital, Kuopio, Finland.
Seppo HelisalmiInstitute of Clinical Medicine-Neurology, University of Eastern Finland, Yliopistonranta 1C, 1627, 70211, Kuopio, Finland.
Annakaisa HaapasaloA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Heli Koivumaa-HonkanenInstitute of Clinical Medicine-Psychiatry, University of Eastern Finland, Kuopio, Finland.
Sanna-Kaisa HerukkaInstitute of Clinical Medicine-Neurology, University of Eastern Finland, Yliopistonranta 1C, 1627, 70211, Kuopio, Finland.
Anne M RemesInstitute of Clinical Medicine-Neurology, University of Eastern Finland, Yliopistonranta 1C, 1627, 70211, Kuopio, Finland.
Eino SoljeInstitute of Clinical Medicine-Neurology, University of Eastern Finland, Yliopistonranta 1C, 1627, 70211, Kuopio, Finland. eino.solje@uef.fi.ORCID http://orcid.org/0000-0001-9940-9524
University of Eastern Finland · FIKuopio University Hospital · FI

Funding

Academy of Finland 315459Academy of Finland 315460Maud Kuistilan Muistosäätiö -Päivikki ja Sakari Sohlbergin Säätiö -VTR Grant Kuopio University Hospital 5772816Yrjö Jahnssonin Säätiö 20187070
6 · The paper itself

Abstract

Due to the significant clinical overlap between frontotemporal lobar degeneration (FTLD) spectrum disorders and late-onset primary psychiatric disorders (PPD), diagnostic biomarkers reflecting the different underlying pathophysiologies are urgently needed. Thus far, elevated cerebrospinal fluid (CSF) levels of neurofilament light chain (NfL) have been reported in various neurological conditions. Furthermore, recent advancements in ultrasensitive analytical methods (e.g., single molecule array, Simoa) have enabled sensitive and less invasive NfL detection also from blood samples. In this study, we evaluated the potential of serum NfL (sNfL) as a diagnostic tool between FTLD and PPD. We analyzed sNfL levels with Simoa from 125 participants including patients from FTLD (n = 91) and PPD (n = 34) spectra. Our results show that sNfL levels are higher in the FTLD group compared to the PPD group as well as in separate clinical subtypes of FTLD compared to different psychiatric manifestations (i.e., mood or psychotic disorders). At single-subject level, discrimination between FTLD and PPD was possible with 80% sensitivity and 85% specificity (AUC = 0.850, 95% CI 0.776-0.923), and between behavioral variant frontotemporal dementia (bvFTD) and PPD with 79% sensitivity and 85% specificity (AUC = 0.830, 95% CI 0.732-0.908). These findings highlight the potential of sNfL as a discriminating biomarker for FTLD over PPD in patients with wide-ranging behavioral, psychiatric and cognitive symptoms.

Indexed as

Affective Disorders, PsychoticAgedBiomarkersBipolar DisorderDepressive DisorderDiagnosis, DifferentialFemaleFrontotemporal Lobar DegenerationHumansMaleMiddle AgedNeurofilament ProteinsPsychotic DisordersSchizophreniaSensitivity and SpecificityBiomarkersneurofilament protein LNeurofilament ProteinsBiomarkerFrontotemporal dementiaFrontotemporal lobar degenerationNeurofilament light (NfL)Psychiatric disorderssNfL

Identifiers

PMID31595378
PMCPMC6954884
OpenAlexW2980306730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.